|Day Low/High||9.93 / 10.47|
|52 Wk Low/High||4.41 / 10.47|
Top-Line Data on Track for 3Q17
Three names show how fast biotechs can become oversold when the market acts in knee-jerk fashion.
Ionis Pharmaceuticals, Alnylam Pharmaceuticals, Amicus Therapeutics and Minerva Neurosciences were among the biotech movers in premarket trading on Monday.
In trading on Monday, shares of Amicus Therapeutics Inc crossed below their 200 day moving average of $6.78, changing hands as low as $6.73 per share. Amicus Therapeutics Inc shares are currently trading down about 1.7% on the day.
Three small-cap biotechs with attractive risk/reward profiles.
Investors in Amicus Therapeutics Inc saw new options become available this week, for the May 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the FOLD options chain for the new May 19th contracts and identified one put and one call contract of particular interest.
Ministry of Health Publishes Final Guidance Covering Reimbursement of Galafold for Fabry Disease
Absent specific policy details, Trump's speech leaves investors guessing about his real plans for the FDA and the drug approval process. He has not yet named an FDA commissioner.
The most recent short interest data has been released for the 01/31/2017 settlement date, which shows a 4,046,337 share increase in total short interest for Amicus Therapeutics Inc , to 32,785,226, an increase of 14.08% since 01/13/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
Investors in Amicus Therapeutics Inc saw new options become available this week, for the February 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the FOLD options chain for the new February 17th contracts and identified the following call contract of particular interest.
Amicus Therapeutics, Nantkwest and Organovo are among the premarket biotech movers on Tuesday.